Versant Venture Management, LLC Crinetics Pharmaceuticals, Inc. Transaction History

Versant Venture Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$16.49 - $27.64 $6.77 Million - $11.3 Million	-410,360 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$19.35 - $28.41 $7.94 Million - $11.7 Million	-410,360 Reduced 50.0%	410,360 $11.7 Million
Q2 2021 Aug 12, 2021	SELL	$15.9 - $21.15 $19.2 Million - $25.6 Million	-1,209,896 Reduced 59.58%	820,720 $15.5 Million
Q2 2020 Jul 20, 2020	BUY	$13.04 - $23.23 $26.5 Million - $47.2 Million	2,030,616 New	2,030,616 $35.6 Billion

246

78.2M

268K

197K

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $3.01B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

Get notified when there are updates to the investment portfolio of Versant Venture Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Versant Venture Management, LLC with notifications on news.